These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30713599)

  • 1. Simplifying checkpoint inhibitor delivery through
    Perales-Puchalt A; Duperret EK; Muthumani K; Weiner DB
    Oncotarget; 2019 Jan; 10(1):13-16. PubMed ID: 30713599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage
    Duperret EK; Trautz A; Stoltz R; Patel A; Wise MC; Perales-Puchalt A; Smith T; Broderick KE; Masteller E; Kim JJ; Humeau L; Muthumani K; Weiner DB
    Cancer Res; 2018 Nov; 78(22):6363-6370. PubMed ID: 30287678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.
    Muthumani K; Block P; Flingai S; Muruganantham N; Chaaithanya IK; Tingey C; Wise M; Reuschel EL; Chung C; Muthumani A; Sarangan G; Srikanth P; Khan AS; Vijayachari P; Sardesai NY; Kim JJ; Ugen KE; Weiner DB
    J Infect Dis; 2016 Aug; 214(3):369-78. PubMed ID: 27001960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.
    Kim H; Danishmalik SN; Hwang H; Sin JI; Oh J; Cho Y; Lee H; Jeong M; Kim SH; Hong HJ
    Cancer Gene Ther; 2016 Oct; 23(10):341-347. PubMed ID: 27632934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections.
    Elliott STC; Kallewaard NL; Benjamin E; Wachter-Rosati L; McAuliffe JM; Patel A; Smith TRF; Schultheis K; Park DH; Flingai S; Wise MC; Mendoza J; Ramos S; Broderick KE; Yan J; Humeau LM; Sardesai NY; Muthumani K; Zhu Q; Weiner DB
    NPJ Vaccines; 2017; 2():18. PubMed ID: 29263874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
    Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
    Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.
    Patel A; DiGiandomenico A; Keller AE; Smith TRF; Park DH; Ramos S; Schultheis K; Elliott STC; Mendoza J; Broderick KE; Wise MC; Yan J; Jiang J; Flingai S; Khan AS; Muthumani K; Humeau L; Cheng LI; Wachter-Rosati L; Stover CK; Sardesai NY; Weiner DB
    Nat Commun; 2017 Sep; 8(1):637. PubMed ID: 28935938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
    Hatae R; Chamoto K
    Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative Therapy, Monoclonal Antibodies and Beyond.
    Di Nicola M; Apetoh L; Bellone M; Colombo MP; Dotti G; Ferrone S; Muscolini M; Hiscott J; Anichini A; Pupa SM; Braud F; Del Vecchio M
    Cytokine Growth Factor Rev; 2017 Dec; 38():1-9. PubMed ID: 29029813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of cancer immunotherapy for esophageal squamous cell carcinoma.
    Kono K; Mimura K; Yamada R; Ujiie D; Hayase S; Tada T; Hanayama H; Min AKT; Shibata M; Momma T; Saze Z; Ohki S
    Esophagus; 2018 Jan; 15(1):1-9. PubMed ID: 29892809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.
    Latta-Mahieu M; Elmer B; Bretteville A; Wang Y; Lopez-Grancha M; Goniot P; Moindrot N; Ferrari P; Blanc V; Schussler N; Brault E; Roudières V; Blanchard V; Yang ZY; Barneoud P; Bertrand P; Roucourt B; Carmans S; Bottelbergs A; Mertens L; Wintmolders C; Larsen P; Hersley C; McGathey T; Racke MM; Liu L; Lu J; O'Neill MJ; Riddell DR; Ebneth A; Nabel GJ; Pradier L
    Glia; 2018 Mar; 66(3):492-504. PubMed ID: 29134678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.
    Fujita K; Terashima T; Mio T
    J Thorac Oncol; 2016 Dec; 11(12):2238-2240. PubMed ID: 27423391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Delivery Systems for Checkpoint Inhibitors.
    Lamichhane P; Deshmukh R; Brown JA; Jakubski S; Parajuli P; Nolan T; Raja D; Badawy M; Yoon T; Zmiyiwsky M; Lamichhane N
    Medicines (Basel); 2019 Jul; 6(3):. PubMed ID: 31373327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.